Nucleoside reverse transcriptase inhibitors suppress HIV replication by blocking reverse transcriptase, an RNAdependent DNA polymerase. These drugs can also affect cellular and mitochondrial DNA polymerases. Mitochondrial DNA polymerase g is particularly sensitive to nucleoside reverse transcriptase inhibitors, and the majority of adverse effects caused by nucleoside reverse transcriptase inhibitors are most likely caused by mitochondrial dysfunction. This article reviews the recent clinical implications of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity and discusses options for management. Curr Opin Infect Dis 13:5±11.
Introduction
Highly active antiretroviral therapy (HAART) is unlikely to eradicate HIV. Faced with this reality, antiviral therapy may be required for several years or for life until other therapeutic options become available. Consequently, the adverse effects of HAART can become obstacles to continued treatment unless managed appropriately. Central to the HAART regimen is the use of two or more nucleoside reverse transcriptase inhibitors (NRTI). Strong evidence suggests that NRTI cause mitochondrial dysfunction and that this phenomenon may explain the majority of adverse effects associated with these drugs [1,2
. . ]. If long-term treatment with HAART is to be considered, a better understanding of mitochondrial toxicity and its management is needed.
Mechanism of toxicity
NRTI require intracellular phosphorylation to the corresponding triphosphate moiety in order to become active. Phosphorylation is catalysed by either cytosolic or mitochondrial deoxyribonucleotide kinases depending on the cell type. The triphosphorylated NRTI then inhibit HIV reverse transcriptase in two ways: (1) by competing against endogenous deoxyribonucleotides for incorporation; and (2) by prematurely terminating transcription once incorporated. NRTI can also be substrates for two intrinsic DNA polymerases of the host, namely DNA polymerase b and g. This latter enzyme, DNA polymerase g, is the sole enzyme responsible for the replication of mitochondrial DNA (mtDNA); the inhibition of mtDNA polymerase g by NRTI can lead to the depletion or mutation of mtDNA and mtDNA encoded enzymes (Fig. 1) . A de®ciency of these enzymes will lead to impaired oxidative phosphorylation, with subsequent mitochondrial dysfunction. Tissue damage results not only from impaired energy (decreased ATP) production, but also from the emergence of reactive oxygen radicals (that are normally neutralized by functional mitochondria) and from a disturbed NADH/NAD + equilibrium between the mitochondrial and cellular membrane. Whether all of these mechanisms play an equivalent role or one mechanism is more important than the other is still a matter of debate.
At present, six NRTI are used in clinical practice: zidovudine (ZDV), zalcitabine (ddC), didanosine (ddI), lamivudine (3TC), stavudine (d4T) and abacavir (ABC).
In-vitro inhibitory constants for DNA polymerase g have been determined but differences in assays make a comparison of the inhibitory constants dif®cult [2 . . ]. Martin et al. compared the inhibitory constants for several NRTI triphosphates, including the six available NRTI, using a single assay [4] . On the basis of these data, a hierarchy of the NRTI in their potency to induce mitochondrial dysfunction in vitro can be made (ddC4ddI4d4T443TC4AZT4ABC). The dif®-culty in extrapolating these data to clinical toxicity is the fact that the ef®ciency in phosphorylation among NRTI also differs. For example, the active form of ddI (ddA-TP) is a potent inhibitor of DNA polymerase g, but only 3% of ddI is converted to this form. Furthermore, different cells have different phosphorylation capacities and this is dependent upon the state of the cell (active or resting). Cells also have varying amounts of mitochondria (anywhere from thousands to none) depending on their cellular energy requirements. Therefore, it is inappropriate to extrapolate results from one cellular or tissue type to another. Finally, a special remark has to be made about 3TC: for this compound it was demonstrated that it not only has the capacity to inhibit the DNA polymerase activity of DNA polymerase g, but it can also function as a substrate of the integral 3'-5'-exonuclease activity of this enzyme. The net result is that 3TC-TP is not likely to induce the termination of mtDNA replication [5] . Af®nity for this exonuclease site has not been studied for other NRTI.
A better understanding of NRTI-induced mitochondrial toxicity will probably come from studies investigating the decrease in mtDNA content or an increase in lactic acid at clinically relevant concentrations [6, 7] . In none of HIV infection and AIDS 6 these studies, however, are all NRTI tested with the same assay, impeding a fair comparison.
So far, the potential of the mitochondrial toxicity of NRTI has only been studied for each of the NRTI separately. Because it is clinical practice to use at least two NRTI in combination, studies on the feasible synergism of these agents in inducing this toxicity are urgently needed.
Clinical spectrum of mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor toxicity
Mitochondrial disease has been studied extensively for many years in pediatrics and neurology [8] . Mitochondrial disease in these settings is usually caused by maternally inherited mutations or deletions of mtDNA genes. Theoretically, the complete depletion of all mtDNA genes by NRTI can potentially induce the complete spectrum of these symptoms, and indeed almost all the long-term side-effects of NRTI can be found within this spectrum. For most of these toxicities, the depletion of mtDNA or mitochondrial dysfunction has been demonstrated in the tissues involved [2 . . ,9 . ,10]. In Table 1 , the clinical symptoms of inherited mitochondrial dysfunction are listed, as well as observed NRTI-induced adverse events. Many of these symptoms have not been described as side-effects of NRTI, possibly because they have not been recognized (i.e. hypogonadism, diabetes, gastrointestinal pseudo-obstruction). Alternatively, many of these symptoms develop early in life, when inherited mitochondrial defects are already present. The observation of possible mitochondrial dysfunction months after perinatal exposure to NRTI might con®rm this early development, because encephalopathy with seizures was among the leading symptoms in that study [11 . . ]. In that retrospective study [11 . . ], eight cases of possible mitochondrial dysfunction were observed in a cohort of 1754 mother±child pairs exposed to NRTI treatment during pregnancy. Two cases resembled Leigh's syndrome and Alper's syndrome with encephalopathy, persistent lactic acidosis, and defects in the mitochondrial respiratory chain complex. Lactic acidosis was observed in three other children. Although it remains unclear why these children developed these symptoms only after 4 months of NRTI exposure (and had therefore had time to replenish the eventually depleted mtDNA and mtDNA encoded proteins), the possibility of mitochondrial toxicity in neonates exposed to NRTI is of great concern and needs to be urgently studied.
Very limited data are available regarding the incidence of NRTI-induced mitochondrial dysfunction, either in children or adults. Prospective studies in large cohorts followed over an extended period of time will provide some of these answers. At present, a simple, noninvasive test is lacking, and to identify mitochondrial dysfunction the clinician therefore has to rely on the collection of clinical symptoms, which are often not very well de®ned.
Lactic acidosis
The most serious presentation of NRTI-induced mitochondrial dysfunction is lactic acidosis. Lactic acidosis can occur abruptly after months of NRTI therapy. It has been associated with ZDV, ddI and d4T, but is likely to occur with all NRTI. In most patients, the initial symptoms include nausea, vomiting, and abdominal pain, rapidly progressing to hyperventilation with severe acidosis, liver failure, and arrhythmia [12,13
. . ]. Prospective data on the incidence are not available, but observational cohorts estimate the incidence at 1.3 per 1000 person-years [13 . . ,14].
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Emerging risk factors
Several independent risk factors can in¯uence NRTIinduced mitochondrial toxicity; these are summarized in Table 2 . Of particular concern is hydroxyurea, a drug used to potentiate the activity of ddI, adefovir, and other adenosine analogues [43] . Reports of adverse effects involving ddI and hydroxyurea include the increased incidence of peripheral neuropathy, neurotoxicity, fatal hepatitis, and prolonged bone marrow suppression [44,45 . ,46
. ,47]. Fatal pancreatitis has also been noted. These observations underscore the narrow therapeutic index for ddI and other NRTI (e.g. adefovir, lodenosine, and d4T); drugs that boost NRTI activity or alter its pharmacokinetic disposition may increase the likelihood or severity of toxicity. Other drugs such as alcohol, highdose tetracycline, and valproic acid are known mitochondrial toxins [48, 49] . The concomitant use of these drugs may exacerbate NRTI-induced mitochondrial toxicity. Finally, hepatic mitochondrial damage has been demon- 
Management options
Mitochondrial toxicity, in general, is reversible upon discontinuation of the NRTI. Myopathy, bone marrow suppression and, to a lesser extent, peripheral neuropathy will resolve in this manner. These side-effects tend to re-occur after rechallenge. Alternative options include dose reduction or continuation of treatment despite the adverse effects. For more severe symptoms, such as lactic acidosis, NRTI should be stopped immediately. Scarce data are available as to whether rechallenging with alternative NRTI is feasible in these cases: in one patient lactic acidosis immediately reoccurred after alternative NRTI were tried [52] .
Pharmacological treatment of mitochondrial dysfunction is currently based upon anecdotal experience and knowledge of the biochemical and enzymatic pathways. Table 3 provides a list of agents that have been tried in inherited mitochondrial diseases with varying success. For the most part, clinical endpoint studies have not been conducted with these agents, and the dosages provided are empiric and are not based on dose-ranging studies. Furthermore, very few of these agents have been used in the context of NRTI-induced mitochondrial toxicity. Vitamins C (ascorbic acid) and E (a-tocopherol) improved ZDV-induced myopathy in vitro [53]. L-Carnitine or acetyl-carnitine has been suggested for NRTI-induced myopathy and peripheral neuropathy because these patients often have carnitine depletion [54, 55] . In three reported cases of lactic acidosis, ribo¯avin (vitamin B 2 ) [56, 57] and ubiquinone (coenzyme Q 10 ) [58] were suggested to improve the clinical condition.
On the basis of these observations, there is a rationale to initiate studies for the evaluation of the possible bene®cial effects of any of these agents in the treatment and prevention of NRTI-induced mitochondrial toxicities. Until such studies are performed, it is reasonable to treat NRTI-induced lactic acidosis with a combination of ribo¯avin, ubiquinone, L-carnitine, and thiamine [13
].
Conclusion
NRTI clearly play a central role in the treatment of HIV. However, the prolonged and combined effect of these drugs on the mitochondria is largely unknown. Hepatic steatosis and lactic acidosis are consequences of mitochondrial dysfunction; we speculate that lipodystrophy may also be related to impairment of the mitochondria. Several risk factors may be involved in the development of mitochondrial toxicity, and the optimal management of this condition has not been determined. Therefore, investigations into the effects of NRTI on mitochondria are necessary to determine the importance of this toxicity and to develop strategies for its prevention and treatment.
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